In this study, we used two NOTCH3 activated NSCLC A549 and H1299 cell lines, and found that EVO exerts anti-NSCLC effects by inhibiting NOTCH3 signaling. The gene discussed is NOTCH3; the disease is non-small cell lung carcinoma.